GEMINI Theranostics

Ovarian cancer (OC) is a high clinical unmet need, with globally over 300.000 diagnoses and 200.000 deaths in 2020. At diagnosis 70% of patients have metastatic disease, limiting treatment options and resulting in a 5-year survival rate of 17%. Existing treatments consist of invasive surgery with chemotherapy with limited efficacy, high recurrence rates and significant side effects. After initial debulking surgery, advanced options like HIPEC or PARP inhibitors are available only to limited patient subsets.

Gemini Theranostics addresses this gap with a theranostic platform targeting the Follicle Stimulating Hormone Receptor (FSHR), a therapeutic target that is expressed in 50-70% of OC patients. Our radioactive products GEMdx and GEMtx are first-in-kind for the targeted and personalized treatment of OC patients.

• GEMdx: Enables PET imaging for accurate diagnosis and patient selection.
• GEMtx: Provides personalized targeted radionuclide therapy.

This scalable solution is effective for primary tumors and in metastatic settings. Preclinical validation shows strong receptor affinity and compatibility with key radioisotopes for diagnosis and therapy. With a total investment of € 8,2M, proof-of-concept clinical translation can be achieved in two years and a phase IIb clinical trial within five years. With GEMdx and GEMtx, Gemini Theranostics taps into a billion dollar market as has been demonstrated for other theranostics in clinical development. In addition, Gemini Theranostics platform is adaptable to other FSHR positive cancers beyond OC. Key for success is the team of Gemini Theranostics, which consists of four highly experienced members with complementary expertise. CEO Dr. Paul Slobbe, director market access in the pharmaceutical industry; CMO Dr. Arthur Braat, nuclear medicine physician at the UMCU and NKI/AvL; CSO Dr. Alex Poot, head of theranostics development at the UMCU; CBO Dr. Peter Krekel, life science entrepreneur and investor.